Great conference this weekend in Amsterdam.
If you use the mobile site you can view Abstracts with Data and Results for all the Tetraphase Poster sessions. Let's just say the results Eravacycline are impressive. :-)
Against Acinetobacter baumannii, including carbapenem-resistant strains, and Stenotrophomonas maltophilia Eravacycline was 2-4 times more potent than Tigecycline.
Against Gram-negative organisms, including drug-resistant phenotypes, isolated from respiratory sources in Europe was 4 time more potent than Tigecycline.
After reviewing the MIC data I bought more TTPH shares. Good luck.
Likely a Tetraphase buyout will follow.
Way, way, way oversold. Someone is going to come in and scoop them up for $12-14/share, just like Hologic did. It's been the plan all along for Kevin.
Seems undervalued to me? No?
"Blood establishments may continue collecting and preparing platelets and plasma if an FDA-approved, pathogen-reduction device is used"
That applies to CERUS.
Sentiment: Strong Buy
Hit the wires an hour ago. CNN and Fox now reporting.
Buy all the CERS you can.
Company is profitable with double digit year over year growth, $250 million cash in the bank, and insurers signing up to cover FoundationOne and FoundationOneHeme in large numbers.